Acelyrin, Inc. (NASDAQ:SLRN) Q3 2024 Earnings Call November 13, 2024 4:30 PM ET

Company Participants

Tyler Marciniak - Vice President, Investor Relations and Corporate Affairs
Mina Kim - Chief Executive Officer
Gil Labrucherie - Chief Financial Officer and Chief Business Officer
Shephard Mpofu - Chief Medical Officer

Conference Call Participants

Tyler Van Buren - TD Cowen
Emily Bodnar - H.C. Wainwright
Vikram Purohit - Morgan Stanley
Samantha Semenkow - Citi

Operator

Good afternoon, and welcome to the Acelyrin, Inc. Third Quarter 2024 Financial Results and Company Update Conference Call. This conference call is being recorded today, November 13, 2024. I would now like to turn the call over to Tyler Marciniak, Vice President of Investor Relations and Corporate Affairs. Tyler?

Tyler Marciniak

Thanks, Victor. Good afternoon, everyone, and thank you for joining us for Acelyrin’s third quarter 2024 conference call. With me today are Mina Kim, our Chief Executive Officer; Gil Labrucherie, our Chief Financial Officer and Chief Business Officer; and Shephard Mpofu, our Chief Medical Officer.

We issued a news release earlier detailing our third quarter financial results and important corporate updates. And before we begin today’s call, I’d like to remind the audience that our remarks may contain forward-looking statements such as those related to the progress of our clinical trials, our future financial operating results and investments and our ability to commercialize our product candidates. We urge you to review the Risk Factors section of our Form 10-Q for the quarter ended September 30, 2024, which was filed today with the SEC and which is also available on our website at Acelyrin.com, along with today’s press release, which identifies certain factors that could cause our actual results, performance and events to differ materially.

Finally, our statements are based on information available to us today, November 13, 2024, and we undertake no obligation to update them as circumstances may change. I would like to now turn the call over to Mina.

Mina Kim

Thanks, Tyler, and thanks, everyone, for joining us today. The first 9 months of 2024 were transformative for Acelyrin, and we’re pleased with the progress we’ve made refocusing our pipeline and corporate strategy. In August, we announced the strategic reprioritization of our pipeline to focus our efforts on developing our lead product candidate, lonigutamab, for which we are in late-stage development as a treatment for thyroid eye disease or TED. Today, we will review our progress with lonigutamab as well as our anticipated upcoming milestones for both that program and our ongoing Phase 2b/3 trial of Izokibep in noninfectious non-interior uveitis.